Nautilus Biotechnology (NasdaqGS:NAUT) FY Conference March 02, 2026 10:30 AM ET Company ParticipantsSujal Patel - Co-Founder and CEOConference Call ParticipantsDan Brennan - Life Science Tools and Diagnostics AnalystDan BrennanGood morning. Dan Brennan, TD Cowen Life Science Tools and Diagnostics Analyst. Day one of the 46th annual TD Cowen Healthcare Conference. Pleased to be joined here on the stage with Co-founder and CEO of Nautilus, Sujal Patel. Sujal, welcome and thank you.Sujal PatelThanks, Dan, and ...

本报讯 记者徐婕报道 近日，国家卫生健康委临床检验中心颁布2025年室间质量评价证书，昆明市延安 医院精准医学中心参加的22个项目均顺利通过评估并获得证书，体现了中心在分子诊断检测能力、数据 分析与报告解读能力、质量控制体系建设等方面达到国家评价标准。 国家卫生健康委临床检验中心作为国家级临床检验质量管理与控制机构，其组织开展的室间质量评价是 国内临床检验领域极具权威性的质量评估。该评价通过向各参评实验室发放同一批次样本，明确检测标 准并收集回报结果，再进行统计学比对与综合研判，以此客观精准评估实验室的检测准确性、校准溯源 能力及持续质量监控水平，进而推动实验室不断完善质量体系、提升服务能力。 市延安医院精准医学中心通过评估的22个项目涵盖三大核心方向。肿瘤精准用药相关检测，能精准找到 肿瘤治疗的关键"靶点"，为癌症患者制定个性化用药方案提供依据；产前筛查与诊断，包括常见唐氏综 合征、爱德华氏综合征、帕陶氏综合征等胎儿染色体异常筛查，以及胎儿染色体核型分析，为备孕家庭 和新生儿健康保驾护航；遗传病及复杂变异检测，像地中海贫血分型、特定遗传病基因异常等检测，能 帮助确诊遗传性疾病，为后续诊疗和遗传咨询提供支持。 ...

Core Viewpoint - The research introduces the XPert model, a dual-branch transformer designed to accurately predict drug-induced cellular perturbation responses, improving patient-specific response prediction accuracy by up to 15.04% while providing mechanistic interpretability [2][15]. Traditional Drug Development Challenges - Traditional drug development follows a "one drug - one target" model, but it is increasingly recognized that drugs interact with multiple molecular targets and pathways, leading to diverse phenotypic outcomes. Understanding genome-wide perturbation effects is crucial for elucidating drug mechanisms and optimizing treatments. However, the scarcity of high-quality perturbation data, especially in clinical settings, and confounding factors in perturbation data limit progress in this field [5]. Innovation of the XPert Model - The XPert model employs a dual-branch transformer architecture that encodes both pre- and post-perturbation cellular states, allowing it to distinguish intrinsic transcription patterns from regulatory changes triggered by perturbations. Each cell is represented as a gene-tagged "sentence" with a global cell state marker [7][8]. Performance of XPert - In benchmark tests, XPert consistently outperformed all baseline models, particularly excelling in challenging cold cell settings. In single-dose, single-time-point prediction tasks, XPert's Pearson correlation coefficient exceeded that of the next best model, TranSiGen, by 36.7%, with a mean squared error reduction of 78.2%. Even when faced with unseen cell lines during training, XPert demonstrated an average improvement of 67.54% over current state-of-the-art models, showcasing significant advancements in generalization capabilities [11][12]. Multi-Dose and Multi-Time Prediction - XPert supports multi-dose and multi-time predictions, accurately elucidating pharmacodynamic trajectories and revealing key molecular events behind drug effects. A case study using Vorinostat demonstrated that increasing doses typically enhanced gene impact, with PCA analysis confirming a clear dose-response gradient. Notably, changes in dose could reverse transcription effects, with XPert effectively capturing these subtle patterns [14]. Clinical Relevance and Insights - The research team explored the relationship between drug-induced transcriptomic changes and clinical responses. Analysis of patient data from Letrozole treatment revealed that responders exhibited stronger transcriptomic responses than non-responders. XPert uniquely identified additional key resistance biomarkers, such as TIAM1 and CDKN1B, which were "invisible" in expression level analyses, highlighting the potential of attention-based methods to uncover gene-phenotype associations and provide insights into resistance mechanisms [17]. Future Outlook - XPert represents a significant advancement in simulating drug-induced perturbation effects through an interpretable and generalizable deep learning framework. With further development, it is expected to become a core component of next-generation computer-aided drug discovery processes and precision medicine platforms [19][20].

Core Viewpoint - The report from Jefferies gives a "Buy" rating for ADICON Holdings (09860) with a target price of HKD 12.60, highlighting the company's strategic positioning in AI medical diagnostics and the significant acquisition of Crown Bioscience, which will enhance its capabilities in drug development and diagnostics [1][2]. Group 1: AI Strategy - ADICON's AI strategy is built around three main pillars: the AI-assisted pathology reading system, which increases reading efficiency by 6-7 times compared to manual methods and includes quality control features for error correction [1]. - The company has launched generative AI tools for clinical doctors, such as "Aixiaoyi" and a clinical large language model developed in collaboration with Huawei, which are integrated into diagnostic workflows for quality control and patient diagnosis [1]. - ADICON has completed a 20-year integration, governance, and cleansing of precision medicine testing data and is exploring commercialization opportunities in areas like commercial insurance, currently performing approximately 10 million AI-assisted image interpretations annually [1]. Group 2: Acquisition of Crown Bioscience - ADICON announced the acquisition of Crown Bioscience for up to USD 204 million, which includes an initial payment of USD 120 million and deferred payments based on performance targets [2]. - Crown Bioscience specializes in translational oncology and immuno-oncology, possessing the largest commercial PDX model library globally and a strong presence in CDX models and biomarker solutions, serving over 1,100 clients, including the top 20 pharmaceutical companies [2]. - The acquisition is expected to significantly enhance ADICON's capabilities in preclinical and translational research, with Crown's data assets and bioinformatics expertise further solidifying its industry position, and it is anticipated that around 23% of ADICON's revenue will come from international markets post-acquisition [2].

Anavex Life Sciences Conference Call Summary Company Overview - **Company**: Anavex Life Sciences (NasdaqGS:AVXL) - **Focus**: Therapeutic discovery and development of targeted treatments for central nervous system (CNS) diseases, particularly Alzheimer's disease and other neurodegenerative conditions [2][3] Key Points and Arguments Alzheimer's Disease and Blarcamesine - **Lead Asset**: Blarcamesine is a once-daily oral small molecule that enhances autophagy through sigma-1 activation, aiming to restore cellular homeostasis [3] - **Market Opportunity**: The global dementia cases are projected to reach 130 million by 2050, highlighting a significant market for effective Alzheimer's treatments [3] - **Clinical Data**: In a phase 2b/3 trial, blarcamesine demonstrated a 36.3% benefit in slowing cognitive decline over 48 weeks, with up to 49.8% in a pre-specified patient population [4] - **Safety Profile**: No deaths or neuroimaging adverse events were reported during the trial, indicating a solid safety profile [4][21] Patient Preferences and Treatment Accessibility - **Oral Dosage Preference**: Surveys indicate a strong preference among patients and caregivers for oral dosage forms for Alzheimer's treatments, as they minimize the need for hospital visits [5][6] - **Quality of Life**: Blarcamesine treatment resulted in significant improvements in quality of life measures, with patients experiencing sustained functionality and independence [30][32] Broader Portfolio and Indications - **Additional Indications**: Anavex is expanding its portfolio to include treatments for Parkinson's disease, Rett syndrome, Fragile X syndrome, infantile spasms, and Angelman syndrome [8][9] - **Anavex 371**: Another oral medication that recently completed a phase 2 study in schizophrenia, showing promising data [9] Financial Position - **Cash Position**: Anavex reported approximately $120 million in cash, sufficient for over three years of operations without debt [35][36] - **Funding Sources**: The company has benefited from non-dilutive funding from organizations like the International Rett Foundation and the Michael Fox Foundation [36] Regulatory and Market Strategy - **Regulatory Discussions**: Ongoing discussions with regulatory agencies, including the EMA, to determine pathways for marketing authorization for blarcamesine [7][12] - **Precision Medicine Approach**: Anavex aims to adopt a precision medicine strategy, focusing on genetically defined populations to enhance treatment efficacy [25][26] Mechanism of Action - **Sigma-1 Activation**: Blarcamesine activates sigma-1 receptors, which are underexpressed in Alzheimer's patients, helping to restore autophagy and cellular homeostasis [38][39] - **Autophagy Restoration**: The mechanism of blarcamesine targets the upstream processes of neurodegeneration, potentially offering a preventative approach to Alzheimer's [10][24] Additional Important Content - **Patient-Centric Focus**: The company emphasizes the importance of patient-oriented treatments that simplify access and reduce caregiver burden [33][34] - **Market Expansion**: The addressable market extends beyond Alzheimer's to include other CNS disorders, indicating a broad potential for growth [35] This summary encapsulates the key insights from the Anavex Life Sciences conference call, highlighting the company's strategic focus on innovative treatments for CNS diseases, particularly Alzheimer's, and its commitment to patient-centered care and financial stability.

扬子晚报网1月9日讯(通讯员刘柳记者万凌云姜天圣)近日，镇江市卫健委下发《关于公布2025年市级临床重点专科中期评估结果的通知》，镇江瑞康医院 骨科成功入选"市级临床重点专科"！这不仅是该院学科建设的里程碑，更标志着镇江经开区迎来首个市级临床重点专科，填补了区域高水平骨科专科空 白。 据悉，镇江瑞康医院骨科由全国助残先进个人、镇江市"健康卫士""镇江名医"刘方刚教授倾力创建，具有一支临床经验丰富、诊疗水平高、技术力量雄厚 的专业人才队伍。医院高度重视学科发展，2025年6月，朱锋教授正式加盟瑞康医院，担任骨科执行主任，具体负责临床、教学与科研工作，瑞康医院骨 科在高层次人才引进、专科建设方面迈出关键一步。 向日葵项目让每个生命得到同样的尊重 2024年11月，瑞康医院共同发起了江苏省残疾人福利基金会瑞康刘方刚助残专项基金向日葵项目，对部分患有脊柱畸形、肢体畸形等需手术治疗的患者进 行救助，计划五年内救助100例患者。项目实施一年多以来，救助了十多位患者，覆盖江苏、河南多地，帮助他们恢复健康，减轻家庭与社会的负担。 瑞康医院骨科表示，将以此次获评市级临床重点专科为契机，持续以患者医疗需求为核心，以数智技术为支撑 ...

Core Insights - Brazil's first public smart hospital has received financing of $320 million (approximately 1.7 billion Brazilian Reais) from the New Development Bank of BRICS, aiming to serve as a model for medical cooperation among BRICS nations [1][2] Group 1: Hospital Development - The smart hospital will be located in São Paulo and is expected to begin operations in 2029, focusing on emergency, critical care, and neurology services [1] - The facility will have 800 beds and an annual capacity to treat approximately 190,000 inpatients, with 25 operating rooms and an estimated annual surgical volume of 27,000 procedures [1] Group 2: Technological Integration - A national-level medical innovation and translational research center will be established, focusing on precision medicine, health data science, clinical algorithms, and medical device validation [2] - The project will implement AI-assisted appointment and triage systems, robotic surgeries, and AI-based hospital management, along with ambulances equipped with high-speed communication technology [2] Group 3: Nationwide Expansion - The "National 'Now There Are Experts' Smart Hospital and Service Network" will invest 4.8 billion Brazilian Reais, with plans to build 14 smart intensive care units across 13 states [2] - Initial projects are expected to be operational by the first half of 2026, covering major cities including Brasília, Rio de Janeiro, and Belo Horizonte [2]

"SPARK-seq的强大之处在于，它首次在单细胞层面实现了从靶点发现到工具分子筛选的闭环。"论文第 一作者、中国科学院杭州医学研究所与湖南大学联合培养博士生罗国焰解释，"这相当于在精准识别疾 病关键'靶标'的同时，也获得了能够干预它的特异性'钥匙'。" 论文共同第一作者、上海交通大学宋佳副研究员补充道："我们开发的数据分析新方法，有效破解了单 细胞数据高维、稀疏背景下的信号提取难题，从而使得这一大规模、系统性的闭环发现成为可能。" 中国科学院杭州医学所研究员吴芩介绍，细胞就像人体内一个个房间，那癌细胞就是"坏了"的房间，但 人体的细胞不计其数，想要精准找到其中的"坏蛋"像是大海捞针。"在治疗癌症时，要么费时费力一个 个找适配的锁和钥匙，要么好的坏的一网打尽，对人体损伤极大。有了SPARK-seq，一次实验就能同时 发现癌细胞的'锁'和匹配的'钥匙'，筛选效率提升百倍以上。" 商报讯(记者冯双通讯员方临明余端)2026年1月1日，国际顶尖学术期刊《Science》在线发表了中国科学 院院士、中国科学院杭州医学研究所所长、浙江省肿瘤医院院长谭蔚泓与吴芩研究员团队合作取得的重 要突破。研究团队成功构建了全球首个能 ...

SPARK-seq平台的诞生解决了这一挑战。相较于传统方法，其筛选效率提升达百倍以上，并能高精 度锁定潜在的癌症标志物与治疗靶点。吴芩表示，"该平台在单细胞层面部署的'分子雷达'，能够大规 模、并行地精准识别细胞表面与疾病相关的靶标，并同步获取能特异性结合它的核酸适体探针。" SPARK-seq作为自主可控的原创性平台，为"无药可靶"疾病的靶点研究与治疗开发提供了全新范 式，使得科研与临床工作者能够基于我国独特的临床资源，系统性地发现具有自主知识产权的新靶点与 新工具。未来，该技术有望推动形成一种"按图索骥"式的精准医疗新模式，快速为不同疾病匹配或定制 治疗分子，提升药物研发的效率和治疗方案的精准度。 （原载于《人民日报海外版》 2026-01-03 02版） 我国科学家成功构建了能够在单细胞分辨率下，同步实现细胞膜表面标志物发现与靶向核酸适体探 针获取的一体化平台——SPARK-seq。该技术为分子识别、原创靶点发现及精准医学研究提供了全新工 具，有望为众多因靶点不明而缺乏有效疗法的疾病开辟新的治疗途径。 由中国科学院杭州医学研究所谭蔚泓院士与吴芩研究员团队合作取得的这项研究成果，1月1日在国 际学术期刊《 ...

来源：人民日报海外版 据新华社杭州1月2日电（记者黄筱）我国科学家成功构建了能够在单细胞分辨率下，同步实现细胞膜表 面标志物发现与靶向核酸适体探针获取的一体化平台——SPARK-seq。该技术为分子识别、原创靶点发 现及精准医学研究提供了全新工具，有望为众多因靶点不明而缺乏有效疗法的疾病开辟新的治疗途径。 由中国科学院杭州医学研究所谭蔚泓院士与吴芩研究员团队合作取得的这项研究成果，1月1日在国际学 术期刊《科学》上线。 细胞膜蛋白是药物作用的关键靶点，而核酸适体是一类能够高特异性、高亲和力结合靶标分子的寡核苷 酸。然而，传统的核酸适体筛选方法效率低、过程繁杂，且难以在生理相关环境下系统发现全新的疾病 标志物。 SPARK-seq平台的诞生解决了这一挑战。相较于传统方法，其筛选效率提升达百倍以上，并能高精度锁 定潜在的癌症标志物与治疗靶点。吴芩表示，"该平台在单细胞层面部署的'分子雷达'，能够大规模、 并行地精准识别细胞表面与疾病相关的靶标，并同步获取能特异性结合它的核酸适体探针。" SPARK-seq作为自主可控的原创性平台，为"无药可靶"疾病的靶点研究与治疗开发提供了全新范式，使 得科研与临床工作者能够基于 ...